Mgc Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.
Key Metrics
PE ratio
-
PB ratio
53.00
Dividend yield
Beta
1.65
Market cap
$121.01M
Enterprise value
$100.7M
Company profile
| Primary activities | MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines. |
|---|---|
| Industry / Sector | Drug Manufacturers—Specialty & Generic / Healthcare |
| Website | http://www.mgcpharma.com.au |
| Mailing address | 1202 Hay Street West Perth WA 6005 Australia |
| Phone / Fax | 61 8 6382 3390 / |
| Share registry | COMPUTERSHARE INVESTOR SERVICES PTY LIMITED |
Dividends
Mgc Pharmaceuticals does not pay dividends.
Company Executives
As of May 2021, following are the company executives and directors listed on Mgc Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Brett Anthony Mitchell | Exec. Chairman | 47 | 260.53k |
| Mr. Roby Reuven Zomer | Co-Founder, CEO, MD & Exec. Director | 348.53k | |
| Mr. Nativ Segev | Founder & Non-Exec. Director | 324.04k | |
| Mr. Daniel Kendall | Chief Financial Officer | ||
| Dr. Nadya Lisodover | Chief Research Officer | ||
| Mr. Amir Polak | CTO & Head of Pharmaceutical Production | ||
| Ms. Nicole Godresse | Global Chief Sales Officer | ||
| Ms. Sabina Suljakovic | Head of the Quality Assurance Department | ||
| Ms. Rachel Jelleff Kerr | Company Sec. (Leave of Absence) | ||
| Hugh Winters | Chief Exec. Officer of MGC Derma |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-974.14%
Return on assets
-58.25%
Return on equity
-414.10%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Mgc Pharmaceuticals is 121.01M and its enterprise value is 100.7M. The enterprise value to revenue ratio of MXC is 96.49.
The MXC's stocks Beta value is 1.65 making it 65% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Mgc Pharmaceuticals (MXC)
Mgc Pharmaceuticals (ASX:MXC) Frequently Asked Questions
1. What is Mgc Pharmaceuticals's Stock Symbol?
Mgc Pharmaceuticals trades on ASX under the ticker symbol "MXC".
2. What is Mgc Pharmaceuticals's stock price today?
One share of MXC stock can currently be purchased for approximately $0.053.
3. How can I contact Mgc Pharmaceuticals?
Mgc Pharmaceuticals's mailing address is 1202 Hay Street West Perth WA 6005 Australia. The company can be reached via phone at 61 8 6382 3390.
4. What is Mgc Pharmaceuticals's official website?
The official website of Mgc Pharmaceuticals is http://www.mgcpharma.com.au.
5. Which share registry manages Mgc Pharmaceuticals's stock?
Mgc Pharmaceuticals's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.